Search

Find exactly what you’re looking for.
Search

Service
Location
Showing 1-20 of 100 results

Josh Pasker, Vice Chair of Saul Ewing's Public Finance Practice, will be speaking on May 16, 2024, during the LeadingAge Inhouse Counsel Conference. Josh's topic will be financing issues and the impact on senior living communities.

In a conversational 30-minute forum over Zoom, Saul Ewing attorneys hosted a discussion on emerging industry developments and common issues that cannabis businesses face today. This month's program featured content covering current regulatory landscape and how it impacts your business. Interested in...

​On February 21, 2024, the Pennsylvania Supreme Court (the "PA Supreme Court") issued its decision in Ursinus College v. Prevailing Wage Appeals Board. The Pa Supreme Court unanimously affirmed the Pennsylvania Commonwealth Court's decision that a construction project financed with tax-exempt bonds...

Saul Ewing attorneys hosted a timely discussion on topics relating to Minnesota’s new adult-use cannabis law. During this one-hour program, we examined the implications of the law for all Minnesota employers, including those relating to drug testing and drug-free workplace policies. We also...

January 26, 2024 - With AI poised to reshape the practice of law and businesses in every industry, Saul Ewing is pleased to partner with the ABA’s Intellectual Property Litigation Committee in forming the AI Subcommittee. The AI Subcommittee will monitor legal and technological developments in this...

Josh Pasker will be speaking at The Authorities Webinar "ABC’s of Arbitrage - What to Remember in a Higher Rate Environment" on November 8, 2023. Why is this topic important? With a historically low interest rate environment over the last several years, issuers of tax-exempt bonds such as municipal...

​On May 18, 2023, the Supreme Court unanimously affirmed the Federal Circuit's decision, Amgen Inc. v. Sanofi , 987 F.3d 1080 (Fed. Cir. 2021), that the claims of two of Amgen's patents were invalid for lack enablement. The involved patents, US 8,829,165 and US 8,859,741, are directed to monoclonal...

For More Information
Contact us